Skip to content

A Trial of Accelerated Fractionation in Localised Invasive Bladder Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN82138783
Enrollment
Unknown
Registered
2002-08-19
Start date
1988-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder (advanced) Cancer Bladder

Interventions

1. Schedule A: Radiotherapy, an accelerated fractionation schedule of 60.8 Gy given in thirty-two fractions over 26 days. Radiotherapy is given twice daily (morning dose of 1.8 Gy and 2.0 Gy in the af

Sponsors

The Institute of Cancer Research (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Stage T2 or T3 NXMO carcinoma of the bladder defined either by clinical findings or by histopathology 2. If nodes are assessed N1 patients (single node <2 cm) are eligible, N2 and N3 patients are excluded 3. Patients with severe concurrent general medical illness especially those with inflammatory bowel disease, other malignancies (except skin cancer), recent myocardial infarction (within 3 months) or previous major pelvic surgery are excluded

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026